UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~April~~May 91, 2025

89bio, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39122

36-4946844

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

655 Montgomery Street, Suite 1500

San Francisco, CA 94111

(Address of principal executive offices, including zip code)

(415) 432-9270

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.001 per share

ETNB

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 72.0102 ~~Regulation~~Results FDof ~~Disclosure~~Operations and Financial Condition.

On ~~April~~May 91, 2025, 89bio, Inc. (the “Company”) ~~made~~issued ~~available~~a anpress ~~updated~~release ~~corporate~~announcing ~~presentation~~its onfinancial results for the ~~Company’s~~quarter ~~website~~ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

AThis ~~copy~~Item of2.02 and the ~~corporate~~Press ~~presentation~~Release isattached ~~furnished~~hereto as Exhibit 99.1, toinsofar ~~this~~as ~~Current~~they ~~Report~~disclose oninformation ~~Form~~regarding ~~8-K~~the ~~and~~Company’s isresults ~~incorporated by reference herein. The exhibit furnished under Item 7.01~~ of ~~this~~operations ~~Current~~and ~~Report~~financial oncondition ~~Form 8-K shall not be deemed to be “filed”~~ for ~~purposes of Section 18 of~~ the ~~Securities~~quarter ~~Exchange~~ended ~~Act of 1934~~March 31, ~~as amended (the “Exchange Act”)~~2025, orare ~~otherwise~~being ~~subject~~furnished to the ~~liabilities~~Securities ofand ~~that section, nor shall it be deemed incorporated by reference in any filing under the~~ Exchange ~~Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing~~Commission.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibits are being furnished herewith:

EXHIBIT INDEX

Exhibit No.		Description
ExhibitNo.		Description
99.1		~~Corporate~~Press ~~Presentation~~Release, dated ~~April~~May 1, 2025
104		Cover ~~page~~Page ~~interactive~~Interactive ~~data~~Data ~~file~~File (embedded within the ~~inline~~Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 9, 2025

/s/ Rohan Palekar

Date: May 1, 2025

/s/ Rohan Palekar

Rohan Palekar

Chief Executive Officer

Filing Compare · 89bio, Inc.